Keros Therapeutics Director Sells Shares Amid Stock Decline
Keros Therapeutics, Inc. (NASDAQ: KROS) director Charles W. Newton executed a sale of 550 shares on June 11, 2026, totaling $5,521. The transaction, conducted under a pre-established Rule 10b5-1 trading plan adopted in March, brings his direct holdings to 12,665 shares. The sale occurs against a backdrop of significant stock depreciation, with shar…